Shiping Luo

Title: Shiping Luo: Innovator in Monoclonal Antibody Development

Introduction

Shiping Luo is a prominent inventor based in Suzhou, China, known for his significant contributions to the field of biotechnology. He holds 2 patents that focus on monoclonal antibodies, which are crucial in the treatment of various cancers. His work has implications for the development of innovative therapeutic solutions.

Latest Patents

Luo's latest patents include a monoclonal antibody that antagonizes and inhibits the binding of human PD-1 antigen to its ligand. This invention details the amino acid sequences of the CDR1, CDR2, and CDR3 in both the light and heavy chain variable regions of the antibody. Additionally, he has developed a mouse monoclonal antibody that inhibits the binding of vascular endothelial growth factor (VEGF) to its receptor. This antibody can be utilized in pharmaceutical compositions for the treatment of solid tumors, including colon cancer and breast cancer.

Career Highlights

Throughout his career, Shiping Luo has worked with notable companies such as Acroimmune Biopharma Co., Ltd. and Suzhou Stainwei Biotech Inc. His expertise in monoclonal antibody development has positioned him as a key figure in the biotechnology sector.

Collaborations

Luo has collaborated with esteemed colleagues, including Hongqun Hu and Zui Chen, to advance research in his field. Their combined efforts have contributed to the development of innovative therapeutic strategies.

Conclusion

Shiping Luo's work in monoclonal antibody development showcases his dedication to advancing medical science. His patents reflect a commitment to creating effective treatments for serious health conditions.